Residency · Residency · Chronic Pain Management

Complex Regional Pain Syndrome: Diagnosis and Evidence-Based Management

Introduction

Complex regional pain syndrome (CRPS) is a debilitating chronic pain condition that typically follows trauma, surgery, or immobilization of a limb. The defining feature is pain that is grossly disproportionate — in both magnitude and duration — to whatever triggered it, accompanied by a constellation of sensory, vasomotor, sudomotor, and motor/trophic abnormalities. CRPS affects roughly 5 to 26 per 100,000 person-years, occurs three to four times more frequently in women than men, and most commonly involves the distal extremities.

Budapest Diagnostic Criteria

The Budapest criteria, adopted by the IASP, require four conditions to be met simultaneously. First, the patient must have continuing pain disproportionate to any inciting event. Second, at time of evaluation, there must be at least one objective sign in two or more of the following categories: sensory (hyperesthesia or allodynia), vasomotor (temperature asymmetry greater than 1 degree Celsius, skin color changes or asymmetry), sudomotor/edema (edema, sweating changes or asymmetry), and motor/trophic (decreased range of motion, motor dysfunction such as weakness, tremor, or dystonia, or trophic changes in hair, nails, or skin). Third, the patient must report at least one symptom in three or more of those same four categories. Fourth, no other diagnosis better explains the findings.

Criteria: ≥1 sign in ≥2 categories AND ≥1 symptom in ≥3 categories, with disproportionate pain and no alternative diagnosis.

CRPS Subtypes

CRPS is classified into three subtypes. Type I (formerly reflex sympathetic dystrophy) occurs without an identifiable nerve injury. Type II (formerly causalgia) occurs in the setting of a confirmed peripheral nerve injury. CRPS-NOS (not otherwise specified) is used for patients who partially meet the Budapest criteria but do not fulfill all requirements.

Pathophysiology

CRPS arises from a complex interplay of multiple pathological mechanisms operating at the peripheral, sympathetic, and central levels.

Neurogenic Inflammation

Peripheral nerve injury triggers the release of substance P and CGRP from nociceptive C-fibers, a process termed neurogenic neuroinflammation. These neuropeptides cause vasodilation, plasma extravasation, and edema in the affected tissues. Pro-inflammatory cytokines — TNF-alpha, IL-1beta, and IL-6 — are elevated in affected tissues and blister fluid. Mast cell activation with increased tryptase levels further contributes to the local inflammatory milieu.

Sympathetic Dysfunction

In CRPS, upregulation of alpha-1 adrenergic receptors on nociceptive afferents creates an abnormal coupling between the sympathetic nervous system and sensory neurons, known as sympatho-afferent coupling. This mechanism underlies the subset of CRPS patients whose pain responds to sympathetic blockade, a phenotype termed sympathetically maintained pain (SMP). Patients whose pain does not respond to sympathetic blocks are classified as having sympathetically independent pain (SIP). The autonomic dysregulation also produces the temperature asymmetry, sweating changes, and skin color alterations characteristic of the condition.

Central Sensitization and Cortical Changes

At the spinal level, central sensitization produces wind-up, expansion of receptive fields, allodynia, and hyperalgesia. At the cortical level, functional MRI and magnetoencephalography studies demonstrate shrinkage of the somatosensory cortical representation of the affected limb. Patients may report body perception disturbances — a sense that the affected limb is foreign, enlarged, or does not belong to them. Motor cortex changes impair motor planning and execution, contributing to the dystonia and weakness seen in advanced cases.

<image>Multi-panel illustration of CRPS pathophysiology showing: Panel A - peripheral neurogenic inflammation with substance P and CGRP release from C-fiber nociceptors causing vasodilation, edema, and mast cell activation; Panel B - sympatho-afferent coupling with upregulated alpha-1 adrenergic receptors on sensory neurons receiving norepinephrine from sympathetic efferents; Panel C - cortical reorganization on a somatosensory homunculus with contracted representation of the affected hand compared to the normal contralateral side.</image>

Clinical Staging

Although staging is debated and many patients do not follow a neat sequential progression, a common clinical framework describes three phases. The acute (warm) phase, spanning roughly the first three months, features burning pain, edema, warmth, erythema, increased sweating, and rapid hair and nail growth. The dystrophic phase, from approximately three to six months, is marked by continued pain, cool and cyanotic skin, reduced sweating, brittle nails, and early osteopenia. The atrophic (chronic) phase, beyond six months, presents with intractable pain, pale and cool skin, contractures, muscle atrophy, severe osteoporosis, and trophic skin changes. It is important to recognize that this staging model is considered an oversimplification, and the clinical course is often nonlinear.

Diagnostic Investigations

No single test confirms CRPS, but several investigations support the diagnosis and help exclude alternatives. Three-phase bone scintigraphy shows characteristic diffuse periarticular uptake in the affected limb, with sensitivity of 50-70% and specificity of 80-90% in early CRPS. Plain radiographs may reveal patchy osteopenia in the affected limb, and comparison views are helpful. Quantitative sensory testing documents the sensory abnormalities. Autonomic testing can confirm resting skin temperature asymmetry (greater than 1 degree Celsius) and abnormalities on quantitative sudomotor axon reflex testing. MRI may show bone marrow edema and soft tissue enhancement and is particularly useful for excluding alternative diagnoses.

Graded Motor Imagery (GMI)

Graded motor imagery is a sequential rehabilitation approach specifically designed to target the cortical reorganization that underlies CRPS. It consists of three progressively challenging stages. The first stage, laterality recognition training, has patients identify left versus right limb images on flash cards. This activates premotor and motor cortex without provoking pain and is practiced three times daily for two weeks. The second stage, imagined movements, involves patients visualizing performing movements of the affected limb without actually moving it, which activates motor planning circuits. This is also practiced for two weeks. The third stage is mirror therapy, in which the unaffected limb is reflected in a mirror to create the visual illusion of normal movement in the affected limb, providing visual cortical feedback that helps correct the disrupted cortical body schema. This phase is practiced for two to four weeks.

Randomized controlled trials demonstrate significant pain reduction (NRS reduction of 2-3 points) and improved function with the GMI protocol, and the Moseley protocol remains the most studied approach.

<image>Three-panel clinical illustration demonstrating the graded motor imagery sequence for CRPS of the right hand: Panel 1 shows laterality recognition training with a patient viewing and identifying left/right hand images on a computer screen; Panel 2 depicts imagined movements with the patient sitting quietly with eyes closed visualizing hand opening and closing; Panel 3 shows mirror therapy setup with the affected right hand hidden behind a mirror while the patient moves the left hand, seeing its reflection as if it were the right hand moving normally.</image>

Pharmacotherapy

Bisphosphonates carry the strongest pharmacological evidence in CRPS, with a number needed to treat of 3-4. Options include alendronate (40 mg/day for 8 weeks), intravenous pamidronate, and intravenous neridronate; their benefit derives from both anti-osteoclastic and anti-inflammatory effects. Corticosteroids, such as prednisolone 30 mg/day tapered over 2-4 weeks, are effective in acute or warm-phase CRPS with prominent inflammatory features. Gabapentinoids — gabapentin (up to 3600 mg/day) and pregabalin (150-600 mg/day) — have modest evidence for the neuropathic pain component. Nortriptyline or amitriptyline at 25-75 mg at bedtime provides dual analgesic and sleep-promoting benefits. Topical agents including lidocaine 5% patches, the capsaicin 8% patch, and compounded creams containing ketamine and gabapentin can be useful adjuncts. Low-dose subanesthetic ketamine infusions represent an emerging option for refractory CRPS, though they require a monitored setting. Finally, free radical scavengers such as DMSO 50% cream may have a role, and vitamin C at 500 mg/day has evidence for preventing CRPS after fractures.

Interventional Treatments

Sympathetic Nerve Blocks

For upper extremity CRPS, the stellate ganglion block involves fluoroscopic or ultrasound-guided injection of local anesthetic at the C6-C7 level. It serves as both a diagnostic and therapeutic intervention — a positive response supports the presence of an SMP component and predicts response to further sympatholytic interventions. For lower extremity CRPS, the lumbar sympathetic block is performed under fluoroscopic guidance at the L2-L3 anterolateral vertebral body. A series of 3-6 blocks is recommended when the initial response is positive.

Spinal Cord Stimulation (SCS)

Spinal cord stimulation is indicated for CRPS refractory to six months of conservative management. The landmark Kemler trial, a randomized controlled study, demonstrated significant pain reduction and global perceived effect at five years with SCS plus physical therapy compared to physical therapy alone. Epidural leads are positioned to capture the affected dermatomes — typically cervical for upper extremity and thoracolumbar for lower extremity involvement. Current stimulation paradigms include tonic, high-frequency (10 kHz), burst, and dorsal root ganglion stimulation.

Dorsal Root Ganglion (DRG) Stimulation

DRG stimulation has proven particularly effective for CRPS of the foot, as demonstrated in the ACCURATE trial. It provides more targeted stimulation with less postural variation than traditional SCS and is FDA-approved for CRPS of the lower extremity.

Intrathecal Drug Delivery

Reserved for severe refractory cases, intrathecal drug delivery can include baclofen for CRPS-related dystonia, and ziconotide or low-dose opioids for intractable pain.

Rehabilitation

Physical and occupational therapy form the backbone of CRPS treatment and include graded exposure, desensitization, progressive weight-bearing, edema management, and functional restoration. The stress loading program — consisting of scrubbing and carrying activities — provides proprioceptive input without painful joint movement. Aquatic therapy leverages buoyancy to reduce pain with movement. Psychological support through cognitive behavioral therapy, acceptance and commitment therapy, and pain catastrophizing reduction techniques should be integrated into the rehabilitation plan.

<image>Clinical photograph-style illustration comparing a CRPS-affected left hand and a normal right hand, demonstrating characteristic findings including diffuse edema, shiny and erythematous skin, altered nail growth, reduced range of motion with partially flexed fingers, and temperature asymmetry indicated by color differences. A skin temperature measurement device shows a greater than 2 degree Celsius difference between the two hands.</image>

Clinical Pearls

Early diagnosis and aggressive rehabilitation are the most important determinants of outcome in CRPS; delays beyond six months are associated with significantly worse prognosis. The Budapest criteria have high sensitivity (99%) but only moderate specificity (68%), so maintaining a broad differential diagnosis remains important. Bisphosphonates are underutilized despite having the strongest pharmacological evidence, and they should be considered early in management. Sympathetic blocks serve a dual purpose — they are both diagnostic and therapeutic, and a positive response identifies the SMP component that predicts benefit from further sympatholytic interventions. DRG stimulation has emerged as the preferred neuromodulation modality for focal CRPS, particularly of the lower extremity. Finally, vitamin C at 500 mg daily for 50 days following wrist fracture reduces CRPS incidence and should be prescribed routinely as a preventive measure.

References

1. Harden NR, Bruehl S, Perez RSGM, et al. Validation of proposed diagnostic criteria (the "Budapest Criteria") for complex regional pain syndrome. Pain. 2010;150(2):268-274.
2. Birklein F, Dimova V. Complex regional pain syndrome-up-to-date. Pain Rep. 2017;2(6):e624.
3. Kemler MA, de Vet HCW, Barendse GAM, et al. Effect of spinal cord stimulation for chronic complex regional pain syndrome Type I: five-year final follow-up of patients in a randomized controlled trial. J Neurosurg. 2008;108(2):292-298.
4. Moseley GL, Gallace A, Spence C. Is mirror therapy all it is cracked up to be? Current evidence and future directions. Pain. 2008;138(1):7-10.

Read this lecture as Markdown